Effect of oral clodronate on bone pain |
| |
Authors: | I Elomaa T Kylmälä T Tammela J Viitanen J Ottelin M Ruutu K Jauhiainen M Ala-Opas L Roos J Seppänen O Alfthan |
| |
Institution: | 1. Department of Radiotherapy and Oncology, University of Helsinki, Finland 2. Central Hospital, Tampere University, Finland 3. Oulu University Central Hospital, Finland 4. North-Karelia Central Hospital, Finland 5. Kemi Central Hospital, Finland 6. IVth Department of Surgery, University of Helsinki, Finland 7. Mikkeli Central Hospital, Finland 8. H?meenlinna Central Hospital, Finland 9. Leiras Clinical Research, Finland 10. Tampere City Hospital, Finland 11. IInd Department of Surgery, Urologic Unit, University of Helsinki, Finland
|
| |
Abstract: | Although osteosclerotic metastases are characteristic of prostatic carcinoma, bone resorption is also accelerated. Since clodronate
inhibits bone resorption and relieves bone pain, we have given it to patients with painful bone disease from prostatic cancer
after failure of hormonal therapy. All patients received estramustine phosphate orally. Simultaneously they were randomly
allocated to clodronate (36) and placebo (39) groups. Clodronate was given by mouth. The dose was 3.2 g for the first month,
thereafter 1.6 g. Pain relief was more distinct in the clodronate group where one third of patients were totally free of bone
pain. The use of analgesics stopped in 38% of patients on clodronate and in 18% on placebo which effect probably belongs to
estramustine phosphate. Serum calcium concentration decreased more markedly in the clodronate group. Clodronate dose of 3.2
g seemed to be more potent than that of 1.6 g. Side effects were uncommon and occurred equally in both groups. No significant
differences were seen in median survival or survival rates between the groups. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|